Ariad’s brigatinib scores 15.6 month PFS rate; Neurimmune backs ALS spinout
Ariad Pharmaceuticals is reporting that its ALK inhibitor brigatinib scored a 55% objective response rate in among patients taking 180 mg. In this same arm the PFS rate was a median 15.6 months. “These updated ALTA trial data show that with additional follow-up, median progression-free survival from brigatinib given post-crizotinib is now 15.6 months, and that this is the same whether assessed by the investigators or an independent review committee,” said D. Ross Camidge, MD, PhD., director of thoracic oncology at the University of Colorado.
Switzerland’s Neurimmune has joined forces with TVM Capital to launch a new biotech which will be responsible for advancing a new drug for ALS. The drug is AP-101, a human monoclonal antibody targeting misfolded SOD1.
Regulus has added two new drug candidates to its pipeline. They are RGLS5040, an anti-miR targeting microRNA-27 (miR-27) for the treatment of cholestatic diseases, and RGLS4326, an anti-miR targeting microRNA-17 (miR-17) for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
With Paul Truex stepping up to the executive chairman’s role at Anthera, J. Craig Thompson has been named CEO. Christopher Henney, meanwhile, has stepped down as chairman but remains on the board.